<DOC>
	<DOCNO>NCT02828774</DOCNO>
	<brief_summary>Using phage library extensively pre-absorbed series normal cell type , isolate phage specifically internalized B-CLL cell newly diagnose untreated CLL patient . Peptide sequence derive Next Generation Sequencing ( NGS ) . NGS-based study contribute improved understanding cancer heterogeneity order tailor treatment patient base individual makeup tumor . However use NGS derive phage display peptide sequence far rare ( 22 ) . Traditionally , exposure target recovery elution , phage clone isolate titration bacterial lawn . It technically demand labour intensive select analyze 15 sometimes thousand clone recover . Therefore information potentially important sequence miss . NGS allow sequence entire recover phage pool provide far detailed bioinformatic analysis peptide sequence motif . RNA CLL cell use RNA-seq expression sequencing . The wide application NGS combination bioinformatics tool begin revolutionize cancer research , diagnosis therapy . The peptide RNA sequence data afford bioinformatic test correlation exome expression clinical parameter pattern peptide sequence internalize CLL cell different patient . This information crucial answering question 1 , 2 3 discussed page 1 . The result analysis probably allow identification specific receptor target peptide . The aim stage research identify candidate target peptide . Once identify , research need identify receptor bind . Regarding question 4 , currently little publish information therapeutic potential PDCs leukemia . Using two peptide isolate target murine A20 leukemic cell , prepare multi-drug PDCs ( use technology develop ) animal model , test ability enhance survival quality life CLL bearing animal .</brief_summary>
	<brief_title>Peptide-drug-conjugates Personalized , Targeted Therapy Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Methodology A : CLL specific peptide : ( Specific aim 1 ) Whole blood sample receive healthy volunteer newly diagnose untreated CLL patient accord Helsinki permit . 0432-13-RMC . ( Rabin Medical Center ) Acquisition sample follow additional 80 patient cover additional Helsinki submission underway . Lymphocytes separate use Ficoll B cell isolate use B-cell isolation kit . The B-cells healthy volunteer aliquot isolated cell patient frozen later use ( see D : ) . The remain patient cell divide two fraction . One use RNA extraction . The exposed `` Absorbed '' phage library pre-absorbed normal cell . After incubation , cell wash phage bound cell membrane elute recovered . Cells lysed lysate retain . Phage eluate lysate ( membrane-bound internalize respectively ) amplify separately E.coli . The amplified phage isolate DNA prepared NGS . Sequencing carry external core facility ( The Technion Genome Center ) . . B : Bioinformatic analysis peptide sequence ( Specific aim 1 ) I ) Sequencing peptide : Sequence read obtain phage DNA library generate analyzed high-throughput sequencing ( Illumina HiSeq system ) . Quality control check perform use FastQC tool . The read process trim adaptor remove consensus sequence either side use Cutadapt software ( 23 ) . The remain fragment tag contain peptide ' DNA sequence expect 21 nucleotide length . Next , BioString package Bioconductor framework use translate nucleotide sequence , number occurrence peptide sequence calculate find frequent peptide . Following normalization library size , peptide sequence count different patient library compare find common sequence . Sequences membrane-bound pool fraction subtract internalized pool fraction remove membrane-bound clone may successfully elute CLL cell . The sequence remain internalized pool serve candidate peptide-conjugate therapy . A univariate logistic regression approach use test possible association peptide count clinical genetic finding . When clinical parameter treat continuous variable , linear regression implement . Candidate peptide query PepBank database ( 24 ) order check know related cancer disease condition apoptosis angiogenesis . Finally , bioinformatic pipeline script develop automate bioinformatics analysis step . II ) RNA-seq detect gene expression pattern fusion gene : The main aim RNA-seq analysis detect specific gene expression pattern correlate peptide sequence clinical parameter . These expression pattern give clue cell surface receptor expression intracellular pathway activity . Patients divide base peptide sequence internalize B-CLL cell , statistical test perform order detect differentially express gene . Pathway analysis perform order infer functional change may shade light possible role peptide receptor cell signal cascade . Trim galore software use adapter trim , remove low quality base end read . Trimmed read map human genome ( hg38 ) use TopHat2 software . The number read overlap annotate gene count use HT-seq python package . DESeq within Bioconductor framework use normalization differential expression analysis use variant Fisher 's exact test . The Generally Applicable Gene-set Enrichment ( GAGE ) method apply detect down-regulated pathway . RNA-seq also use detect fusion gene event patient 's cancer cell use independent validation method test sensitivity peptide-dye conjugate use disease monitoring . For aim , three different tool TopHat-fusion , defuse ChimeraScan use identify fusion transcript . Several filtration step apply order remove low-quality candidate describe , candidate detect three tool choose RT-PCR validation . C : Syntheses Peptides conjugate ( Specific aim 1,2,3 ) Peptides synthesize use solid-phase chemistry . In first stage project , two peptide specific A20 mouse leukemic cell already identify synthesize , namely HIS SER THR PRO SER SER PRO ( Peptide 1 ) ASP SER SER LEU PHE ALA LEU ( Peptide 2 ) . In late stage ( see ) , select human CLL specific peptide synthesized sequence become available . Only peptides multiple repeat read ( &gt; 5 ) ( see B ) select ( maximum 3 per patient ) represent phage clone great propensity induce uptake cell . Peptides synthesize fluorescent dye- drug-conjugates base previous work target multi-drug conjugate ( 21 ) . We employ drug differ mechanisms action , nitrogen mustard Chlorambucil use treat elderly CLL patient , microtubule inhibitor Combretastatin 4A , know induce apoptosis CLL cell ( 25 ) . Purity composition product verify HPLC LC/MS . Syntheses carry external supplier . D : In vitro validation peptide specificity PDC activity : ( Specific aim 1 , 2 , 3 ) Specificity peptide : The specificity target peptide demonstrate incubate peptide-dye conjugate target control cell . For mouse CLL system , A20 cell use target cell normal mouse splenic lymphocyte primary culture mouse skin epithelial cell use control cell . For human CLL system , patient CLL cell normal human lymphocytes HUVEC cell use target control cell respectively . Cells incubate FITC-labeled peptide 4oC 37oC , wash analyzed binding internalization respectively . Binding evaluate flow cytometry internalization confocal microscopy . Cytotoxicity PDCs : Target control cell incubate 24 48 hr increase concentration ( 0-50uM drug equivalent ) free drug PDCs . Percent Growth Inhibition assess XTT assay . Cytotoxic A20 specific PDCs evaluate vivo ( see E : ) . Cell culture system : The A20 cell line grow maintain FBS supplement RPMI culture medium . Normal primary culture maintain selective medium . On hand , survival human CLL cell culture dependent several unique microenvironmental factor , include antigen stimulation B-cell BCR , T cell help CD40-CD40L interaction , stimulation bone marrow stromal cell-derived CXCL12 chemokine stimulation Toll-Like Receptor 9 . These condition mimic vitro ( 26 ) addition culture medium anti-IgM ( crosslink BCRs ) , co-culture fibroblast express CD40L , addition recombinant CXCL12 CpG dinucleotides respectively . These condition use test specificity efficacy human PDCs cryopreserved sample patient CLL cell normal human lymphocyte ( control ) . E : Animal study use A20 mouse model CLL ( Specific aim 3 ) While several antibody-drug conjugate treatment CLL use test ( 16 ) , little publish information efficacy PDCs disease . Therefore aim study behavior A20 specific PDCs animal model CLL , accord protocol approve Ariel University Institutional Animal Ethics Committee , permit . IL-47-08-13 . To validate calibration CLL development , A20 cell inject intravenously Balb/c mouse development CLL symptom monitor . Usually take 40-50 day . Study A ) : At point , know little effective treatment schedule PDCs . For reason , base publish literature , first test systemic tolerance animal drug PDCs inject group non-tumor bearing mouse intraperitoneally 1 , 7.5 15 mg/Kg one Chlorambucil Combretastatin 4A contain PDC every third day 3 week . Animals monitor systemic morbidity survival . On basis result , initial treatment schedule select compare two concentration two PDCs . Animals show initial sign CLL treat follow survival development CLL symptom least additional 70 day . Study B : Using Study A result , effective PDC study . The PK drug conjugate analyze administer 5 drug concentration , include use Study A . Blood sample draw tail vein 0.25 , 0.5 , 1 , 2 , 5 , 10 24 hr . PDC extract analyzed LC/MS content integrity . Drug concentration analyze HPLC use calculate standard PK parameter [ Cmax ; TCmax ; T1/2 ] . Based experiment , additional treatment protocol devise aim maintain maximum blood PDC concentration treatment period . The protocol test additional group animal . After treatment period , animal follow survival development CLL symptom least additional 70 day . F : Detection CLL cell animal patient whole blood . ( Specific aim 1 2 ) The aim experiment assess potential CLL-specific peptide-dye conjugate detect CLL cell blood sample . Calibration experiment carry three level . 1 . Cell doping : Cryopreserved sample patient CLL cell add either RPMI culture medium normal human blood ( three concentration ) . B-cells isolate describe A incubated appropriate Peptide-dye conjugate 30mins 37OC . Cells wash analyzed peptide bind flow cytometry . Similarly , A20 cell add normal mouse blood test A20 specific peptide-dye conjugate . 2 . Animal model : Using animal model describe , blood sample take once/week tumor induction phase . After RBC lysis , remain cell incubate peptide-dye conjugate , wash analyse flow cytometry . Furthermore , sample take once/fortnight animal survive Study B analyse Minimal residual Disease relapse . 3 . Patient follow : Aliquots blood sample take routine follow CLL patient use . Cells incubated appropriate Peptide-dye conjugate 30mins 37OC . Cells wash analyzed peptide bind flow cytometry . G : Statistics Cytotoxicity PDCs free drug assess calculate % Growth Inhibition treat versus untreated cell . Experiments perform triplicate repeat thrice . In animal study , survival assess use Kaplan-Meier curve . Additional statistic related bioinformatic analysis describe detail section 1.7-B .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>CLL patient intend receive treatment 30 day recruitment study.. CLL patient receive treatment 30 day recruitment study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>